title: CG0009, a novel glycogen synthase kinase 3 inhibitor, induces cell death through cyclin D1 depletion in breast cancer cells.
abstract: Glycogen synthase kinase 3α/β (GSK3α/β) is a constitutively active serine/threonine kinase involved in multiple physiological processes, such as protein synthesis, stem cell maintenance and apoptosis, and acts as a key suppressor of the Wnt-β-catenin pathway. In the present study, we examined the therapeutic potential of a novel GSK3 inhibitor, CG0009, in the breast cancer cell lines, BT549, HS578T, MDA-MB-231, NCI/ADR-RES, T47D, MCF7 and MDA-MB-435, from the NCI-60 cancer cell line panel. Assessment of cytotoxicity, apoptosis and changes in estrogen-signaling proteins was performed using cell viability assays, Western blotting and quantitative real-time PCR. CG0009 enhanced the inactivating phosphorylation of GSK3α at Ser21 and GSK3β at Ser9 and simultaneously decreased activating phosphorylation of GSK3β at Tyr216, and induced caspase-dependent apoptosis independently of estrogen receptor α (ERα) expression status, which was not observed with the other GSK3 inhibitors examined, including SB216763, kenpaullone and LiCl. CG0009 treatment (1 µmol/L) completely ablated cyclin D1 expression in a time-dependent manner in all the cell lines examined, except T47D. CG0009 alone significantly activated p53, leading to relocation of p53 and Bax to the mitochondria. GSK3 inhibition by CG0009 led to slight upregulation of the β-catenin target genes, c-Jun and c-Myc, but not cyclin D1, indicating that CG0009-mediated cyclin D1 depletion overwhelms the pro-survival signal of β-catenin, resulting in cell death. Our findings suggest that the novel GSK3 inhibitor, CG0009, inhibits breast cancer cell growth through cyclin D1 depletion and p53 activation, and may thus offer an innovative therapeutic approach for breast cancers resistant to hormone-based therapy.
authors.affiliation: Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
authors.forename: Hyun Mi
authors.initials: HM
authors.lastname: Kim
authors.forename: Choung-Soo
authors.initials: CS
authors.lastname: Kim
authors.forename: Je-Hwan
authors.initials: JH
authors.lastname: Lee
authors.forename: Se Jin
authors.initials: SJ
authors.lastname: Jang
authors.forename: Jung Jin
authors.initials: JJ
authors.lastname: Hwang
authors.forename: Seonggu
authors.initials: S
authors.lastname: Ro
authors.forename: Jene
authors.initials: J
authors.lastname: Choi
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D001552:Benzazepines / Q000494:pharmacology; D001943:Breast Neoplasms / Q000201:enzymology / Q000378:metabolism*; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D019938:Cyclin D1 / Q000378:metabolism*; D005260:Female; D038362:Glycogen Synthase Kinase 3 / Q000037:antagonists & inhibitors / Q000378:metabolism*; D006801:Humans; D007211:Indoles / Q000494:pharmacology; D018021:Lithium Chloride / Q000494:pharmacology; D008301:Maleimides / Q000494:pharmacology; D060888:Real-Time Polymerase Chain Reaction
chemical_list: D000970:Antineoplastic Agents; D001552:Benzazepines; D007211:Indoles; D008301:Maleimides; C417521:SB 216763; C119620:kenpaullone; D019938:Cyclin D1; D038362:Glycogen Synthase Kinase 3; D018021:Lithium Chloride
references.citation: Nature. 2000 Jul 6;406(6791):86-90
references.pmid: 10894547
references.citation: Nature. 2008 Oct 30;455(7217):1205-9
references.pmid: 18806775
references.citation: Cancer Res. 2008 Aug 15;68(16):6643-51
references.pmid: 18701488
references.citation: Trends Biochem Sci. 2004 Feb;29(2):95-102
references.pmid: 15102436
references.citation: Cancer Res. 2007 May 15;67(10):4564-71
references.pmid: 17495324
references.citation: Oncogene. 2009 Apr 30;28(17):1892-903
references.pmid: 19330026
references.citation: Neurochem Res. 2007 Apr-May;32(4-5):577-95
references.pmid: 16944320
references.citation: Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):7951-5
references.pmid: 12048243
references.citation: Chem Biol Interact. 2011 Feb 1;189(3):177-85
references.pmid: 21111724
references.citation: Curr Med Chem. 2008;15(15):1493-9
references.pmid: 18537625
references.citation: Genes Dev. 2000 Oct 1;14(19):2501-14
references.pmid: 11018017
references.citation: Genes Dev. 1998 Nov 15;12(22):3499-511
references.pmid: 9832503
references.citation: EMBO J. 1990 Aug;9(8):2431-8
references.pmid: 2164470
references.citation: Nat Rev Drug Discov. 2004 Jun;3(6):479-87
references.pmid: 15173837
references.citation: J Cell Sci. 2003 Apr 1;116(Pt 7):1175-86
references.pmid: 12615961
references.citation: Cancer Res. 2005 Mar 15;65(6):2076-81
references.pmid: 15781615
references.citation: Development. 2008 Mar;135(5):789-98
references.pmid: 18263841
references.citation: Nat Rev Cancer. 2002 Jul;2(7):489-501
references.pmid: 12094235
references.citation: Mol Endocrinol. 2007 Oct;21(10):2427-39
references.pmid: 17609434
references.citation: Blood. 2007 Jul 15;110(2):735-42
references.pmid: 17463171
references.citation: Breast Cancer Res Treat. 2008 Sep;111(1):55-63
references.pmid: 17899364
references.citation: Cancer Res. 2005 Oct 1;65(19):9012-20
references.pmid: 16204075
references.citation: Br J Cancer. 2009 Dec 15;101(12):2005-14
references.pmid: 19920820
references.citation: Trends Mol Med. 2002 Mar;8(3):126-32
references.pmid: 11879773
references.citation: J Biol Chem. 2003 Dec 5;278(49):48872-9
references.pmid: 14523002
references.citation: Mol Cancer Ther. 2007 Mar;6(3):1151-8
references.pmid: 17363508
references.citation: Breast Cancer Res Treat. 2007 Jul;104(1):13-9
references.pmid: 17004106
references.citation: Hum Pathol. 2010 Dec;41(12):1657-63
references.pmid: 20709358
references.citation: J Biol Chem. 2002 May 17;277(20):17901-5
references.pmid: 11834740
references.citation: Mol Cell Biol. 2005 Oct;25(19):8444-55
references.pmid: 16166627